Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

The future of the weight loss market might not revolve around GLP-1 drugs.

Three Fool.com contributors have identified what they believe are no-brainer growth stocks to buy in October. Here's why they ...

If you're looking for two magnificent growth stocks to start your long-term portfolio (or add to a portfolio) and have $500 ...

Apart from mistrust in the larger pharmaceutical world and Pfizer's inability to find a major break after the pandemic ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Anders Carlson, Matt Orzech welcome challenges from Greg Joseph, Peter Bowden ...

Leaders worried the former president could force Ukraine to cede land to Russia in exchange for a ceasefire if he wins the election ...

Elon Musk Unveils the Long-Awaited Robotaxi and Tesla's Autonomous Future ...